• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus
【24h】

Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus

机译：巨噬细胞迁移抑制因子（MIF）作为类风湿性关节炎和系统性红斑狼疮的治疗靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ABSTRACT Introduction. Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine with upstream regulatory roles in innate and adaptive immunity and is implicated in the pathogenesis of autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Several classes of MIF inhibitors such as small molecule inhibitors and peptide inhibitors are in clinical development. Areas covered. The role of MIF in the pathogenesis of RA and SLE is examined; the authors review the structure, physiology and signaling characteristics of MIF and the related cytokine D-DT/MIF-2. The preclinical and clinical trial data for MIF inhibitors are also reviewed; information was retrieved from PubMed and ClinicalTrials.gov using the ^g>MIF, D-DT/MIF-2, CD74, CD44, CXCR2, CXCR4, Jab-1, rheumatoid arthritis, systemic lupus erythematosus, MIF inhibitor, small molecule, anti-MIF, anti-CD74, and peptide inhibitor. Expert opinion. Studies in mice and in humans demonstrate the therapeutic potential of MIF inhibition for RA and SLE. MIF- directed approaches could be particularly efficacious in patients with high expression MIF genetic polymorphisms. In patients with RA and SLE and high expression MIF alleles, targeted MIF inhibition could be a precision medicine approach to treatment. Anti-MIF pharmacotherapies could also be steroid-sparing in patients with chronic glucocorticoid dependence or refractory autoimmune disease.
机译：摘要介绍。巨噬细胞迁移抑制因子（MIF）是一种具有先天性和适应性免疫上游调节作用的血吸虫炎性细胞因子，并且涉及自身免疫性疾病的发病机制，包括类风湿性关节炎（RA）和全身狼疮红斑（SLE）。几类MIF抑制剂如小分子抑制剂和肽抑制剂在临床发育中。覆盖的区域。 MIF在RA和SLE发病机制中的作用被检查了;作者审查了MIF和相关细胞因子D-DT / MIF-2的结构，生理学和信号特性。还审查了MIF抑制剂的临床前和临床试验数据;使用^ g> mif，d-dt / mif-2，cd74，cd44，cxcr2，cxcr4，jab-1，类风湿性关节炎，全身性鼠红斑，mif抑制剂，小分子，抗-MIF，抗CD74和肽抑制剂。专家意见。小鼠和人类的研究证明了MIF抑制Ra和SLE的治疗潜力。在高表达MIF遗传多态性患者中，MIF定向方法可能是特别有效的。在Ra和SLE和高表达MIF等位基因患者中，靶向MIF抑制可能是治疗的精确药物方法。抗MIF药物治疗也可以是慢性糖皮质激素依赖性或难治性自身免疫疾病患者的类固醇备灌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号